Skip to main content
. 2008 Sep;6(2):54–67. doi: 10.3121/cmr.2008.793

Figure 2.

Figure 2.

Rates of glucose infusion needed to maintain plasma glucose at the target value of 130 mg/dL after subcutaneous injection of glargine, NPH, and ultralente and after continuous subcutaneous insulin infusion (CSII) of lispro in patients with type 1 diabetes.36 (Copyright 2000 American Diabetes Association. From Diabetes Care 2000; 49:2142–2148. Reprinted with permission from The American Diabetes Association.)